Processa Pharmaceuticals, Inc. PCSA
Processa Pharmaceuticals, Inc. ("Processa," "we" or the "Company") was incorporated under the laws of the State of Delaware on March 29, 2011. Our principal executive office is located at 601 21st
Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, and, if applicable, amendments to those reports filed or furnished
pursuant to Section 13(a) or 15(d) of the Exchange Act, as soon as reasonably practicable
after we electronically file such material with, or furnish it to, the Securities and Exchange Commission (SEC), as well as our Code of Ethics and Code of Conduct. The SEC also maintains
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | $0 | $0 | — | — | — | — | $5.0K |
| Gross profit | — | — | — | — | — | — | — | — | — | $5.0K |
| R&D | — | — | $5.8M | $11.5M | $6.9M | $3.2M | $2.3M | $3.1M | $964.2K | $1.5M |
| SG&A | $6.2M | $4.8M | $5.7M | $8.8M | $4.7M | $3.3M | $1.6M | $1.4M | $838.3K | $70.0K |
| Total operating expenses | — | — | — | — | — | — | — | — | $1.8M | $1.9M |
| Operating income | -$14.0M | -$12.1M | -$11.5M | -$27.5M | -$12.1M | -$15.1M | -$3.9M | -$4.5M | -$1.8M | -$1.9M |
| Interest expense | — | — | — | — | $362 | $281.1K | $36.7K | $161.2K | $59.1K | $245.4K |
| Pre-tax income | -$13.6M | -$11.9M | -$11.1M | -$27.4M | -$12.0M | -$15.4M | -$4.0M | -$4.7M | -$1.9M | -$337.2K |
| Income tax | — | — | — | — | $530.6K | $1.0M | $602.7K | $902.8K | $258.6K | — |
| Net income | $13.6M | -$11.8M | -$11.1M | -$27.4M | -$11.4M | -$14.4M | -$3.4M | -$3.8M | -$1.9M | -$1.9M |
| EPS, basic | -10.36 | -96.78 | -8.48 | -34.05 | -0.75 | — | — | — | -0.06 | -0.07 |
| EPS, diluted | -10.36 | -96.78 | -8.48 | -34.05 | -0.75 | -2.54 | -0.70 | -0.71 | -0.06 | -0.07 |
| Shares, diluted (wtd. avg.) | $1.3M | $122.4K | $1.3M | $805.5K | $15.3M | — | — | — | $32.6M | $29.3M |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $5.5M | $1.2M | $4.7M | $6.5M | $16.5M | $15.4M | $691.5K | $1.7M | $2.8M | $1.1M |
| Total current assets | $5.7M | $1.9M | $5.6M | $8.4M | $18.3M | $16.2M | $1.0M | $2.0M | $3.0M | $2.3M |
| Property, plant and equipment | $3.8K | $5.0K | $2.6K | — | — | $484 | $8.9K | $17.4K | $25.8K | $22.4K |
| Other intangibles | — | — | — | — | $8.1M | $8.8M | $9.6M | $10.4M | — | — |
| Total assets | $7.8M | $3.2M | $5.8M | $8.6M | $26.5M | $25.2M | $10.9M | $12.5M | $3.0M | $2.4M |
| Accounts payable | $1.1M | $880.9K | $311.6K | $327.5K | $218.9K | $320.7K | $75.6K | $292.1K | $50.7K | $14.6K |
| Short-term debt | — | — | — | — | — | — | — | $230.0K | $2.4M | — |
| Total current liabilities | $2.2M | $1.5M | $730.6K | $998.6K | $971.0K | $1.2M | $1.2M | $645.7K | $2.6M | $97.7K |
| Total liabilities | $2.2M | $1.5M | $797.5K | $1.1M | $978.4K | $2.3M | $2.9M | $2.8M | $2.6M | $97.7K |
| Retained earnings | -$100.8M | -$87.2M | -$75.4M | -$64.2M | -$36.8M | -$25.4M | -$11.0M | -$7.6M | -$3.9M | -$2.0M |
| Total equity | $5.6M | $1.7M | $5.0M | $7.5M | $25.5M | $22.9M | $8.0M | $9.7M | $373.2K | -$2.3M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$11.4M | -$11.2M | -$8.1M | -$9.6M | -$8.7M | -$3.1M | -$2.8M | -$3.7M | -$1.7M | -$2.2M |
| Depreciation and amortisation | $1.2K | $782 | $222 | — | $484 | $8.4K | $8.4K | $8.4K | $1.9K | $1.4K |
| Stock-based compensation | $857.5K | $629.5K | $1.1M | $8.8M | $3.4M | $2.7M | $510.5K | $74.1K | — | $6.7K |
| Capital expenditure | — | $3.2K | $2.8K | — | — | — | — | — | $20.6K | $23.8K |
| Investing cash flow | -$850.0K | -$3.2K | -$2.8K | — | — | — | — | -$22.3K | $1.0M | -$1.0M |
| Financing cash flow | $16.6M | $7.7M | $6.3M | -$388.8K | $9.8M | $17.9M | $1.7M | $2.6M | $2.4M | $4.3M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001493152-26-029326.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| AKTX | Akari Therapeutics Plc | $1.79T | — | — |
| LLY | ELI LILLY & Co | $1.08T | 50.1x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $663.28B | 25.0x | 6.0% |
| ONC | BeOne Medicines Ltd. | $529.55B | 1,885.6x | 40.2% |
| ABBV | AbbVie Inc. | $453.19B | 108.7x | 8.6% |
| MRK | Merck & Co., Inc. | $370.89B | 20.6x | 1.3% |
| ABT | ABBOTT LABORATORIES | $188.69B | 29.1x | 5.7% |
| PFE | PFIZER INC | $162.16B | 20.9x | -1.6% |